Alps Advisors Inc. increased its position in shares of Horizon Pharma PLC (NASDAQ:HZNP) by 9.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 160,878 shares of the biopharmaceutical company’s stock after purchasing an additional 14,011 shares during the period. Alps Advisors Inc. owned 0.10% of Horizon Pharma PLC worth $2,040,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of HZNP. Bank of Montreal Can grew its stake in shares of Horizon Pharma PLC by 16.3% during the second quarter. Bank of Montreal Can now owns 9,809 shares of the biopharmaceutical company’s stock worth $116,000 after purchasing an additional 1,378 shares in the last quarter. Sheaff Brock Investment Advisors LLC grew its stake in shares of Horizon Pharma PLC by 5.0% during the second quarter. Sheaff Brock Investment Advisors LLC now owns 10,500 shares of the biopharmaceutical company’s stock worth $125,000 after purchasing an additional 500 shares in the last quarter. Family Management Corp acquired a new position in shares of Horizon Pharma PLC during the second quarter worth $131,000. Ballentine Partners LLC acquired a new position in shares of Horizon Pharma PLC during the second quarter worth $139,000. Finally, Teacher Retirement System of Texas grew its stake in shares of Horizon Pharma PLC by 12.8% during the second quarter. Teacher Retirement System of Texas now owns 12,941 shares of the biopharmaceutical company’s stock worth $154,000 after purchasing an additional 1,466 shares in the last quarter. Hedge funds and other institutional investors own 83.80% of the company’s stock.

A number of equities analysts recently commented on the stock. Jefferies Group LLC boosted their target price on shares of Horizon Pharma PLC from $16.00 to $21.00 and gave the stock a “buy” rating in a research note on Tuesday, November 7th. Stifel Nicolaus reiterated a “buy” rating and set a $20.00 target price on shares of Horizon Pharma PLC in a research note on Sunday, October 22nd. Cantor Fitzgerald reiterated a “buy” rating and set a $17.00 target price on shares of Horizon Pharma PLC in a research note on Monday, September 11th. Piper Jaffray Companies set a $18.00 target price on shares of Horizon Pharma PLC and gave the stock a “buy” rating in a research note on Sunday, October 15th. Finally, ValuEngine downgraded shares of Horizon Pharma PLC from a “buy” rating to a “hold” rating in a research note on Friday, September 1st. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and eleven have assigned a buy rating to the stock. Horizon Pharma PLC presently has a consensus rating of “Buy” and a consensus price target of $18.42.

TRADEMARK VIOLATION WARNING: This report was originally reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this report on another website, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The original version of this report can be viewed at https://theolympiareport.com/2017/11/13/alps-advisors-inc-has-2-04-million-position-in-horizon-pharma-plc-hznp.html.

Shares of Horizon Pharma PLC (HZNP) traded up $0.32 on Monday, hitting $13.57. 2,833,700 shares of the stock traded hands, compared to its average volume of 3,526,486. Horizon Pharma PLC has a twelve month low of $9.45 and a twelve month high of $21.98. The firm has a market capitalization of $2,223.93, a P/E ratio of 9.83, a price-to-earnings-growth ratio of 1.15 and a beta of 1.32. The company has a quick ratio of 1.52, a current ratio of 1.64 and a debt-to-equity ratio of 1.89.

Horizon Pharma PLC (NASDAQ:HZNP) last announced its earnings results on Monday, November 6th. The biopharmaceutical company reported $0.26 earnings per share for the quarter, topping the consensus estimate of $0.22 by $0.04. Horizon Pharma PLC had a negative net margin of 45.28% and a positive return on equity of 20.22%. The business had revenue of $271.60 million during the quarter, compared to the consensus estimate of $259.74 million. During the same quarter in the prior year, the firm earned $0.70 earnings per share. The business’s quarterly revenue was up 30.1% compared to the same quarter last year. sell-side analysts forecast that Horizon Pharma PLC will post 0.72 earnings per share for the current fiscal year.

Horizon Pharma PLC Profile

Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.

Want to see what other hedge funds are holding HZNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Horizon Pharma PLC (NASDAQ:HZNP).

Institutional Ownership by Quarter for Horizon Pharma PLC (NASDAQ:HZNP)

Receive News & Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.